A Phase III Randomized Study of Chimeric Anti-GD2 in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Transplant (Companion Study to A3973)
This partially randomized phase III trial studies isotretinoin with dinutuximab,
aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone
following stem cell transplant in treating patients with neuroblastoma. Drugs used in
chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different
ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person''s white
blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with
or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.